• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

541.70 -29.68 (-5.19%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,239,840
Open 570.00
Bid (Size) 538.00 (40)
Ask (Size) 541.40 (360)
Prev. Close 571.38
Today's Range 541.27 - 577.02
52wk Range 409.07 - 609.35
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet
October 01, 2026
Check out the companies making headlines yesterday: United Therapeutics (NASDAQ:UTHR): Biotechnology company United Therapeutics (NASDAQ:UTHR) rose by 13.6% ... 
Via StockStory
Topics Intellectual Property
News headline image
1 Mid-Cap Stock to Research Further and 2 That Underwhelm
October 01, 2026
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory

Performance

52-Week Range 11.1% below 52-week high
541.70
409.0752W Low 609.3552W High
1 Week 7.5% below 1-week high
470.761W Low 585.791W High

United Therapeutics Corporation - Common Stock (UTHR) traded between $409.07 and $609.35 over the past 52 weeks and last traded at $541.70, 11.1% below its 52-week high. Over the past week it ranged between $470.76 and $585.79.

Past 12 Months
+11.6%
+10.1%
-1.0%
-3.2%
+9.1%
+22.2%
1W +$56.16
1M +$49.68
3M -$5.55
6M -$17.95
YTD +$44.98
1Y +$98.26

UTHR was +22.2% over the past year, -3.2% over six months, +9.1% year to date, +11.6% in the last week.

12 Months vs Market
UTHR
+22.2%
DIA
+9.9%
SPY
+15.0%
QQQ
+23.7%
IWM
+15.4%

Over the past 12 months UTHR returned +22.2% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

Volume & Liquidity 1.98× 3-mo avg
Today 1,239,840 3-mo avg 627.1K
1W
1.5M
1M
946.6K
3M
627.1K
6M
565.2K
YTD
542.3K
1Y
537.8K

UTHR most recently traded 1,239,840 shares against a 3-month average daily volume of 627.1K.

More News

Read More
News headline image
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
September 30, 2026
From United Therapeutics
Via Business Wire
News headline image
Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today
September 30, 2026
Via StockStory
Topics Intellectual Property
United Therapeutics (NASDAQ:UTHR): A Growth-at-a-Reasonable-Price Candidate ↗
September 24, 2026
Via Chartmill
United Therapeutics (NASDAQ:UTHR) Screens as a High-Quality, Debt-Free Stock ↗
September 21, 2026
Via Chartmill
United Therapeutics (NASDAQ:UTHR) Fits the Growth-at-a-Reasonable-Price Model ↗
September 03, 2026
Via Chartmill
News headline image
United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions ↗
September 25, 2026
Via MarketBeat
News headline image
Why United Therapeutics (UTHR) Shares Are Falling Today
September 24, 2026
Via StockStory
News headline image
1 Cash-Heavy Stock to Target This Week and 2 We Question
September 11, 2026
Via StockStory
News headline image
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest
September 08, 2026
Via StockStory
Topics Artificial Intelligence
United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns ↗
August 20, 2026
Via Chartmill
United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play ↗
August 13, 2026
Via Chartmill
News headline image
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
September 08, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
3 Profitable Stocks We’re Skeptical Of
September 03, 2026
Via StockStory
News headline image
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
September 02, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
September 01, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
August 28, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
3 Cash-Producing Stocks We Keep Off Our Radar
August 26, 2026
Via StockStory
News headline image
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
August 24, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
August 17, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript ↗
August 12, 2026
Via The Motley Fool
Topics Earnings
News headline image
United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions
August 12, 2026
Via StockStory
Topics Earnings
News headline image
UTHR Q2 2026 Deep Dive: Product Pipeline Developments Offset Competitive Pressures
August 06, 2026
Via StockStory
News headline image
United Therapeutics Q2 Earnings Call Highlights ↗
August 05, 2026
Via MarketBeat
Topics Earnings

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?
Yes, United Therapeutics Corporation - Common Stock is publicly traded.
What exchange does United Therapeutics Corporation - Common Stock trade on?
United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for United Therapeutics Corporation - Common Stock?
The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
What is the current price of United Therapeutics Corporation - Common Stock?
The current price of United Therapeutics Corporation - Common Stock is 541.70
When was United Therapeutics Corporation - Common Stock last traded?
The last trade of United Therapeutics Corporation - Common Stock was at 10/02/26 04:00 PM ET
What is the market capitalization of United Therapeutics Corporation - Common Stock?
The market capitalization of United Therapeutics Corporation - Common Stock is 24.32B
How many shares of United Therapeutics Corporation - Common Stock are outstanding?
United Therapeutics Corporation - Common Stock has 24B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap